AU741802B2 - Treatment of infarcts through inhibition of NF-kappaB - Google Patents

Treatment of infarcts through inhibition of NF-kappaB Download PDF

Info

Publication number
AU741802B2
AU741802B2 AU61719/98A AU6171998A AU741802B2 AU 741802 B2 AU741802 B2 AU 741802B2 AU 61719/98 A AU61719/98 A AU 61719/98A AU 6171998 A AU6171998 A AU 6171998A AU 741802 B2 AU741802 B2 AU 741802B2
Authority
AU
Australia
Prior art keywords
inhibitors
mammal
proteasome
inhibitor
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU61719/98A
Other languages
English (en)
Other versions
AU6171998A (en
Inventor
Stephen Brand
Peter J. Elliott
Alfred L. Goldberg
Louis Plamondon
Francois Soucy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU6171998A publication Critical patent/AU6171998A/en
Assigned to MILLENNIUM PHARMACEUTICALS, INC. reassignment MILLENNIUM PHARMACEUTICALS, INC. Amend patent request/document other than specification (104) Assignors: PROSCRIPT, INC.
Application granted granted Critical
Publication of AU741802B2 publication Critical patent/AU741802B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Organic Insulating Materials (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Artificial Filaments (AREA)
  • Transplanting Machines (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
AU61719/98A 1997-02-15 1998-02-17 Treatment of infarcts through inhibition of NF-kappaB Ceased AU741802B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80193697A 1997-02-15 1997-02-15
US08/801936 1997-02-15
US98833997A 1997-12-03 1997-12-03
US08/988339 1997-12-03
PCT/US1998/003077 WO1998035691A1 (en) 1997-02-15 1998-02-17 Treatment of infarcts through inhibition of nf-kappab

Publications (2)

Publication Number Publication Date
AU6171998A AU6171998A (en) 1998-09-08
AU741802B2 true AU741802B2 (en) 2001-12-13

Family

ID=27122399

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61719/98A Ceased AU741802B2 (en) 1997-02-15 1998-02-17 Treatment of infarcts through inhibition of NF-kappaB

Country Status (14)

Country Link
US (3) US6271199B2 (https=)
EP (1) EP0979096B1 (https=)
JP (1) JP2001511814A (https=)
CN (1) CN1159061C (https=)
AT (1) ATE240113T1 (https=)
AU (1) AU741802B2 (https=)
CA (1) CA2281224A1 (https=)
DE (1) DE69814618T2 (https=)
ES (1) ES2196547T3 (https=)
IL (1) IL131410A0 (https=)
NO (1) NO321203B1 (https=)
NZ (1) NZ337364A (https=)
PT (1) PT979096E (https=)
WO (1) WO1998035691A1 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4215219B2 (ja) * 1997-07-04 2009-01-28 アンジェスＭｇ株式会社 脳保護剤
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US20090042807A1 (en) * 1998-05-20 2009-02-12 Nisar Ahmed Khan Oligopeptide treatment of ischemia reperfusion injury
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
EP1223948A2 (en) * 1999-09-13 2002-07-24 CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US6713459B1 (en) * 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
CA2429163C (en) * 2000-11-16 2013-02-12 The Regents Of The University Of California Marine actinomycete taxon for drug fermentation and product discovery
JP4162491B2 (ja) 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6740674B2 (en) 2001-05-21 2004-05-25 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
ATE502642T1 (de) * 2001-10-05 2011-04-15 Zalicus Inc Kombinationen für die behandlung von immun- entzündlichen erkrankungen
ATE517617T1 (de) * 2001-12-10 2011-08-15 Yansheng Dr Du Behandlung von parkinson erkrankung mit kape
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
AU2004253478A1 (en) * 2003-06-20 2005-01-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
ZA200600473B (en) * 2003-06-20 2007-04-25 Univ California Salinosporamides and methods for use thereof
US7348305B2 (en) 2003-08-28 2008-03-25 Department Of Veterans Affairs, Rehabilitation Inhibitor of cardiac tachyarrhythmias
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
SE0400399D0 (sv) * 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP2266988A1 (en) 2004-04-30 2010-12-29 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US7425580B2 (en) * 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
EP1771194A2 (en) * 2004-07-07 2007-04-11 Biodevelops Pharma Entwicklung GmbH Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface
US20060008454A1 (en) * 2004-07-07 2006-01-12 Dr. Helmut Brunar Use of a compound for enhancing the expression of membrane proteins on the cell surface
US20090191105A1 (en) * 2004-08-30 2009-07-30 Kazuhiro Tanahashi Fractionation Apparatus
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
EP1830838B1 (en) 2004-12-03 2012-10-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating neoplastic diseases
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
EP1912664A2 (en) * 2005-07-06 2008-04-23 Biodevelops Pharma Entwicklung GmbH Use of a compound for enhancing the expression of membrane proteins on the cell surface
WO2007011757A1 (en) * 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
US7691896B2 (en) * 2005-08-10 2010-04-06 President And Fellows Of Harvard College Analogs of salinosporamide A
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
ES2293834B1 (es) * 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
DK2120991T3 (da) * 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
WO2009140287A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
CA2727862C (en) 2008-06-17 2016-04-19 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
EP2527434B1 (en) 2010-01-22 2017-08-09 Japan Science and Technology Agency Probe reagent for measurement of proteolytic activity
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
CN108498532B (zh) 2012-05-09 2021-07-23 坎泰克斯制药股份有限公司 骨髓抑制的治疗
IN2013MU01431A (https=) 2013-04-16 2015-06-26 Cipla Ltd
EP3102585B1 (en) 2014-02-03 2021-05-19 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
TN2016000492A1 (en) 2014-05-20 2018-04-04 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy.
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
JP2018510859A (ja) 2015-03-17 2018-04-19 レオン−ナノドラッグズ ゲーエムベーハー 安定化されたボロン酸化合物を含むナノ粒子
US11897969B2 (en) 2017-10-26 2024-02-13 The Regents Of The University Of California Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661270B2 (en) 1990-03-05 1995-07-20 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
EP0824918B1 (en) * 1995-05-12 2007-03-28 AnGes MG, Inc. REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB
US5942494A (en) 1995-10-06 1999-08-24 The Trustees Of Columbia University In The City Of New York Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70)
JP2000510328A (ja) 1996-03-19 2000-08-15 プロスクリプト・インコーポレイテッド ＩкＢαを部位特異的にリン酸化し得るキナーゼ
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof

Also Published As

Publication number Publication date
CA2281224A1 (en) 1998-08-20
US20030069189A1 (en) 2003-04-10
ES2196547T3 (es) 2003-12-16
US20010053760A1 (en) 2001-12-20
PT979096E (pt) 2003-09-30
NO993935L (no) 1999-10-04
EP0979096B1 (en) 2003-05-14
NO993935D0 (no) 1999-08-16
ATE240113T1 (de) 2003-05-15
US20010002391A1 (en) 2001-05-31
CN1250376A (zh) 2000-04-12
NO321203B1 (no) 2006-04-03
NZ337364A (en) 2001-06-29
HK1025266A1 (en) 2000-11-10
US6271199B2 (en) 2001-08-07
DE69814618D1 (de) 2003-06-18
WO1998035691A1 (en) 1998-08-20
AU6171998A (en) 1998-09-08
DE69814618T2 (de) 2004-03-25
IL131410A0 (en) 2001-01-28
CN1159061C (zh) 2004-07-28
JP2001511814A (ja) 2001-08-14
EP0979096A1 (en) 2000-02-16

Similar Documents

Publication Publication Date Title
AU741802B2 (en) Treatment of infarcts through inhibition of NF-kappaB
WO1998035691A9 (en) Treatment of infarcts through inhibition of nf-kappab
McDonald et al. Liver disease after human marrow transplantation
Berg et al. Side effects of cyclosporin A treatment in patients with rheumatoid arthritis
de Leciñana et al. Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke
Danese et al. Protection by aspirin against experimentally induced arterial thrombosis in dogs
Konishi et al. Carbamazepine-induced skin rash in children with epilepsy
Philp et al. Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis
KR100701539B1 (ko) 멜라가트란의 신규 용도
US7786170B2 (en) Histone deacetylase inhibitor enhancement of trail-induced apoptosis
Hashimoto et al. Treatment of Behçet's disease
HK1025266B (en) Treatment of infarcts through inhibition of nf-kappab
MXPA99007509A (en) Treatment of infarcts through inhibition of nf-kappab
JP2010189438A (ja) 壊死の治療および予防のための組成物および方法
HK1026640A (en) Treatment of infarcts through inhibition of nf-kappab
JPH06228006A (ja) トロンビン阻害剤の眼フィブリン形成阻害のための使用
Lai et al. Efficacy of albendazole–GM6001 co-therapy against Angiostrongylus cantonensis-induced meningitis in BALB/c mice
Flier et al. Anti-inflammatory adjuvant agents in bacterial meningitis
JPH03133927A (ja) 虚血後の心筋機能障害の改善剤
Saglam et al. The effect of captopril on brain apoptosis after burn injury in rats
Buchan Delayed Maturation of Cortical Infarction: Role of Caspasesand NF-K B-Mediated Transcription
JP3169343B2 (ja) アスピリンおよび抗−Ｘａオリゴ糖の組合せを含有する組成物ならびにアスピリンと任意的に組み合わせた抗−Ｘａオリゴ糖の使用
AU2004220717B2 (en) Pharmaceutical preparation for the treatment of inflammatory processes
Fornasa Safety of cyclosporin A in the treatment of dermatological diseases.
US20040101488A1 (en) Method for the prevention of septic shock lethality using curcumin

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: MILLENIUM PHARMACEUTICALS, INC.

Free format text: FORMER NAME: PROSCRIPT, INC.

TH Corrigenda

Free format text: IN VOL 14, NO 26, PAGE(S) 4782 UNDER THE HEADING CHANGE OF NAME(S) OF APPLICANT(S) THE NAME OF THE APPLICANT IN REGARD TO PATENT APPLICATION 61719/98 HAS BEEN AMENDED TO READ: MILLENNIUM PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF AN INVENTOR TO READ PETER J. ELLIOTT